BioFactura’s biosimilar ustekinumab shows comparable PK to Stelara® in Ph I trial

by Bioblast Editor | Oct 14, 2022 | Biosimilars updates

BioFactura has announced successful completion of its Ph I trials relating to biosimilar ustekinumab candidate BFI-751. The trial in Australia and New Zealand involved 226 subjects and demonstrated bioequivalence of BFI-751 to the US and EU versions of Janssen’s...

Celltrion’s ustekinumab biosimilar Ph III trials

by Bioblast Editor | Sep 7, 2022 | Biosimilars updates

Yonhap News Agency reported that Celltrion’s ustekinumab biosimilar CT-P43 Ph III trials demonstrated comparable efficacy and safety to Janssen’s Stelara®. Data from the global 28-week study in 509 plaque psoriasis patients was presented at the European Academy of...

Formycon publishes preliminary 2022 half year financial results

by Bioblast Editor | Sep 6, 2022 | Biosimilars updates

German based biosimilars focussed company Formycon published its preliminary and unaudited financial results for the first half of 2022. Formycon reported a turnover of Euro 17.6 million in the first six months of 2022. The preliminary report does not include the...

Alvotech publishes financial results

by Bioblast Editor | Aug 31, 2022 | Biosimilars updates

Alvotech published its first half 2022 financial results, reporting a revenue growth to over $40 million compared to $2.0 million in the first half of 2021 due to recent launches of adalimumab (AV02) in Canada and Europe. The company has $128.4Min cash/equivalents...

Formycon reports on ustekinumab biosimilar Ph III trials

by Bioblast Editor | Aug 16, 2022 | Biosimilars updates

Formycon has reported that its ustekinumab biosimilar candidate FYB202 showed comparable efficacy and safety to Janssen’s Stelara in a Ph III clinical trial in plaque psoriasis patients. Formycon’s extended pharmacokinetics Ph I study has commenced. This follows...